Slide 1: Cover letter to stock exchanges
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com February 17, 2023 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corpo
Slide 2: Q3 FY23 Investor Presentation
Q3 FY23 Investor Presentation February 2023 B I O C O N L I M I T E D 1
Slide 3: Core Values
Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high- quality, affordable therapies that can lower costs, increase access and improve treatment outcomes. Value Creation through Innovation & Differe
Slide 4: Biocon at a Glance
Biocon at a Glance ₹ 8,397 Cr | ~15,000+ Rank #8 Among Top 10 Global Total Employees* $ ~1.1 bn Biotech Employers** Revenue* 1,300+ 100+ 7 Patents* cGMP approvals from International regulatory agencies Manufacturing units* 120+ 15 of top 20 Top 28 Countries where our pharma companies Products within
Slide 5: Building Biocon
Building Biocon B I O C O N L I M I T E D 44
Slide 6: Biocon: One Company, with multiple value propositions across its verticals
Biocon: One Company, with multiple value propositions across its verticals From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality & affordable healthcare products & services, globally Ensuring access through quality, affordability, reliability ▪ Lead
Slide 7: Generics Business at a Glance
Generics Business at a Glance Presence in R&D team of 5 90+ 750+ 100+ State-of-the-art cGMP approvals 450+ global countries including U.S., facilities received from international scientists customer reach Europe & large EMs regulatory agencies Portfolio comprises 90+ 500+ 300+ 60+ APIs Generic DMFs
Slide 8: Generics: API & Formulations - Growth Levers
Generics : API & Formulations - Growth Levers Strengths built over the years Product Portfolio Expansion Capacities Additions & Expansion • Expertise in fermentation technology, large scale • API - Expanding portfolio beyond fermentation and • Immunosuppressants API (Visakhapatnam) chromatography &
Slide 9: Generics: Our Key APIs and Formulations
Generics : Our Key APIs and Formulations APIs* F O R M U L AT I O N S Therapeutic Molecule Therapeutic Area Molecule Dev. Markets: ex- Therapeutic Area Molecule US MoW1 Area US Apixaban Mycophenolate Mofetil Rosuvastatin Calcium EU Atorvastatin Mycophenolate Sodium Simvastatin Dabigatran Immunosuppr
Slide 10: Biosimilars Business at a Glance
Biosimilars Business at a Glance Global reach in 3 25+ R&D team of 100+ State-of-the-art cGMP approvals 450+ countries including U.S., manufacturing received from key regulatory Europe and EMs scientists sites agencies 965+ Portfolio comprises 8 >5M patents granted 20 biosimilars Commercial Patients
Slide 11: Biosimilars: Unique, fully integrated capabilities from lab to market
Biosimilars: Unique, fully integrated capabilities from lab to market Research & Development Global Scale Manufacturing Commercialization Process & Product Development Mammalian & microbial tech platforms Commercial footprint in 100+ countries 3 Manufacturing Sites Analytical & Bioanalytical Capabil
Slide 12: Biosimilars: Leading global player with a strong track record of success
Biosimilars: Leading global player with a strong track record of success Built on a 40+ year legacy of cutting-edge science …with a strong track record in an attractive market • Invested >$1B in biosimilars ahead of its peers to build • Achieved many ‘firsts’ in the industry - first to receive exper
Slide 13: Biosimilars: Acquisition of Viatris' global biosimilars business
Biosimilars: Acquisition of Viatris’ global biosimilars business Provides full Accelerates BBL’s ownership direct entry in of collaboration many markets assets, as well as across AMs & EMs, Viatris’ rights for in- takes us closer to licensed biosimilars > USD 3B Acquisition - Amongst Largest patient
Slide 14: Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars
Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars Oncology Immunology Ophthalmology Bone Health Diabetes Others Vaccines Therapy Area • Pegfilgrastim • Adalimumab • RHI Approved or • Trastuzumab • Etanercept • Glargine U100 Commercial • Bevacizumab • Aspart • Denosumab • Ustek
Slide 15: Biosimilars: Portfolio offers multiple shots on goal to drive sustainable growth
Biosimilars: Portfolio offers multiple shots on goal to drive sustainable growth BIOCON BIOLOGICS GROWTH DRIVERS Today < 2 years 2-4 years >4 years - Pegfilgrastim - Bevacizumab (US) - Aflibercept - Pertuzumab - Trastuzumab - Aspart (US) - Denosumab - Glargine 300 IU - Bevacizumab - Adalimumab (US)
Slide 16: Novel Molecules: Itolizumab
Novel Molecules : Itolizumab Pushing to deliver impactful innovations in collaboration with Equillium Inc. ✓ Pivotal Phase III Study initiated in Mar ’22 for use in First-Line treatment of Acute GVHD; Acute Graft- patient dosing initiated Itolizumab Versus-Host ✓ European Commission granted Orphan D
Slide 17: Novel Molecules: Bicara Therapeutics - BCA101
Novel Molecules : Bicara Therapeutics* - Dual Action | Dual Impact The precision of targeted therapies | The power of tumor modulators ✓ Lead product candidate, BCA101 (EGFR / TGF-β-trap) demonstrates tumor target engagement and clinical activity ✓ Monotherapy activity in difficult to treat post-pem
Slide 18: Research Services: Syngene capabilities across the value chain
Research Services : Syngene has capabilities spanning the value chain, facilitating integration Research business Development and Manufacturing business Discovery Services Dedicated R&D Centres Development Services Manufacturing Services Flexible Platform with capability across Ring-fenced infrastru
Slide 19: Research Services (Syngene): Key Growth Levers
Research Services (Syngene) : Key Growth Levers Platform Play in Discovery Integrated Solutions in Extension and expansion of Development Services and clinical Scaling up Manufacturing Services Dedicated Centres Services supplies • Flexible platform solutions with • Integrated Solutions from process
Slide 20: Quarterly Highlights
Quarterly Highlights B I O C O N L I M I T E D 19 19
Slide 21: Financial Highlights: Q3 FY23 (1/2)
Financial Highlights: Q3 FY23 (1/2) Consolidated (in INR Cr.) Q3 FY23 Q3 FY22 YoY % Total Revenue 3,020 2,223 36 Biosimilars +54% | Research +23% | Generics +18% Core EBITDA1 1,069 715 49 % Margin 36% 33% Net R&D spend at ₹337Cr, up ₹199 Cr vs Q3 FY22 EBITDA 723 537 35 Forex Loss of ₹44Cr vs gain of
Slide 22: Financial Highlights: Q3 FY23 (2/2)
Financial Highlights: Q3 FY23 (2/2) Consolidated (in INR Cr.) Q3 FY23 Q3 FY22 YoY % Net Profit 140 187 (25) (before exceptional charge) Exceptional items during Q3 FY23: Exceptional Items (182) - Primarily pertain to deal related expenses of the (net of tax and minority interest) Viatris transaction
Slide 23: Generics: Q3 FY23 Update
Generics: Q3 FY23 Update K E Y H I G H L I G H T S Revenue growth led by increased demand for Immunosuppressant APIs as well as Generic Formulations In INR Cr Q3 FY23 Q3 FY22 YoY % Margins, compared to the previous year were muted due to continued Revenue from 718 607 18 pricing pressure in the US m
Slide 24: Biosimilars: Q3 FY23 Update
Biosimilars: Q3 FY23 Update K E Y H I G H L I G H T S Revenue growth of 54% driven by Viatris deal closure and steady growth in BBL-led business In INR Cr Q3 FY23 Q3 FY22 YoY % R&D investments increased to ₹280 Crores; completed recruitment Revenue from 1,507 981 54 for bDenosumab and bUstekimnumab
Slide 25: Novels: Q3 FY23 Update
Novels : Q3 FY23 Update K E Y H I G H L I G H T S Enrolment continues to ramp up in the pivotal Phase III clinical study of Itolizumab in patients with aGVHD* (EQUATOR study) Patient enrolment also continues for the pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis (equalise study) T
Slide 26: Research Services: Q3 FY23 Update
Research Services: Q3 FY23 Update K E Y H I G H L I G H T S Delivered positive performances in all divisions. Sustained growth in Research divisions - Discovery Services and the Dedicated Centers In INR Cr Q3 FY23 Q3 FY22 YoY % Revenue from Development Services growth primarily driven by repeat orde
Slide 27: Environment, Social, Governance
Environment, Social, Governance B I O C O N L I M I T E D 26 26
Slide 28: ESG: A Culture of Purpose, Ethics & Equity
ESG: A Culture of Purpose, Ethics & Equity Going beyond financials to have a positive impact Recognitions Our ESG Strategy Pillars Published 1st GRI aligned ESG & BRSR Report for FY22 Improve access to high quality therapeutics to drive ‘Patient Equity’ Improved ESG score over Build an empowering an
Slide 29: Annexures
Annexures B I O C O N L I M I T E D 28 28
Slide 30: Biocon's Evolution: Our journey over the last 5 decades
Biocon’s Evolution: Our journey over the last 5 decades Metamorphosis from manufacturer of enzymes to a vertically integrated bio-pharmaceutical player and global CRO & CDMO of global standing. Created tangible differentiators for sustainable growth with focus on research and innovation 1970s-80s 19
Slide 31: With many firsts, Biocon is ahead of the curve
With many firsts, Biocon is ahead of the curve • 1st Indian Life • 1st Clinical Research • 1st company globally to • 1st company in the • 1st Indian Company • 1st anti-CD6 Sciences Company Service Organization get U.S. FDA approval world to develop & to launch a novel monoclonal antibody to get ISO
Slide 32: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 33: Thank You
Thank You B I O C O N L I M I T E D 32 32